Trials / Completed
CompletedNCT02604823
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive, interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV. Following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks. |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2015-11-13
- Last updated
- 2016-11-02
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02604823. Inclusion in this directory is not an endorsement.